Lead(s): Dr Devi Nair
Group Members: Dr Puja Ayrton, Dr Nandini Rao, Dr Mahtab Sharifi
Location: Royal Free Hospital
Overview: The department has dynamic clinical programme managing a clinical cohort of over 500 patients with familial hyperlipidaemia with family screening using cascade testing. The group is at the forefront of involvement in a number of commercial and investigator trials of the PCSK9 inhibitors. As the SAS centre for cardiovascular biomarkers the department is involved in valifdation of newer biomarkers for use in cardiovascular disease. Clinical projects include 1. Progression of Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: Evaluation of the Role of CT Coronary angiography, Carotid Intima-Media Thickness, Novel Bio-markers and polygenic versus Monogenic Determinants of Cardiovascular Disease 2. To evaluate the value of a new cardiovascular biomarker Liproprotein- associated phospholipase A2 (Lp-PLA2) and a non-invasive ultrasound technique, carotid intimal muscle thickness (CIMT) beyond traditional risk factors (TRF) in screening for cardiovascular Disease (CVD) in a South Asian population at high risk of developing vascular disease - a pilot study 3. Investigation of Neutrophil gelatinase associated lipocalin (NGAL) in pre- eclampsia. 4.PCSK9 Levels in patients presenting with Lipid abnormalities. 5. Screening for Fabry’s disease.